Log in

NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Forecast & News

$0.80
+0.07 (+9.59 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.70
Now: $0.80▼
$0.80
50-Day Range
$0.52
MA: $0.64▼
$0.92
52-Week Range
$0.28
Now: $0.80▼
$1.18
Volume509,937 shs
Average Volume462,577 shs
Market Capitalization$13.76 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCC
Previous Symbol
CUSIPN/A
CIK1130166
Webhttp://www.cyclacel.com/
Phone908-517-7330

Debt

Debt-to-Equity Ratio0.08
Current Ratio7.65
Quick Ratio7.65

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales91.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.22 per share
Price / Book0.66

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-7,290,000.00
Net MarginsN/A
Return on Equity-49.11%
Return on Assets-39.36%

Miscellaneous

Employees14
Outstanding Shares17,199,000
Market Cap$13.76 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:CYCC Rates by TradingView

Palm Beach Millionaire Stuns Live Audience (Ad)


The audience GASPED when he revealed how you could collect 100% on your savings every year... for life.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) issued its quarterly earnings results on Wednesday, November, 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.06. View Cyclacel Pharmaceuticals' Earnings History.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals.

What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

Media headlines about CYCC stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cyclacel Pharmaceuticals.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 427,900 shares, an increase of 30.5% from the December 15th total of 328,000 shares. Based on an average daily trading volume, of 201,400 shares, the short-interest ratio is currently 2.1 days. Currently, 2.5% of the shares of the company are short sold. View Cyclacel Pharmaceuticals' Current Options Chain.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include McEwen Mining (MUX), NovaBay Pharmaceuticals (NBY), Celldex Therapeutics (CLDX), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), CTI BioPharma (CTIC), Immunomedics (IMMU), Madrigal Pharmaceuticals (MDGL) and Bausch Health Companies (BHC).

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.80.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $13.76 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: What is a Call Option?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel